Literature DB >> 28712536

Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3.

Helena Lee1, Andrew Lotery2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28712536     DOI： 10.1016/S0140-6736(17)31622-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Polarized AAVR expression determines infectivity by AAV gene therapy vectors.

Authors:  Bradley A Hamilton; Xiaopeng Li; Alejandro A Pezzulo; Mahmoud H Abou Alaiwa; Joseph Zabner
Journal:  Gene Ther       Date:  2019-04-08       Impact factor: 5.250

2.  RPE65 mutation frequency and phenotypic variation according to exome sequencing in a tertiary centre for genetic eye diseases in China.

Authors:  Shiqiang Li; Xueshan Xiao; Zhen Yi; Wenmin Sun; Panfeng Wang; Qingjiong Zhang
Journal:  Acta Ophthalmol       Date:  2019-07-05       Impact factor: 3.761

Review 3.  Managing Bardet-Biedl Syndrome-Now and in the Future.

Authors:  Elizabeth Forsythe; Joanna Kenny; Chiara Bacchelli; Philip L Beales
Journal:  Front Pediatr       Date:  2018-02-13       Impact factor: 3.418
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.